Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate-associated neutropenia

AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic–pharmacodyn...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: van Hasselt, J G Coen, Gupta, Anubha, Hussein, Ziad, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Science Inc 2013
Soggetti:
Pharmacokinetics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3769668/
https://ncbi.nlm.nih.gov/pubmed/23601153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12143
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi